Online citations, reference lists, and bibliographies.
← Back to Search

Molecular-Targeted Therapy For Malignant Mesothelioma

Y. Tada, T. Suzuki, H. Shimada, K. Hiroshima, K. Tatsumi, M. Tagawa
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is an intractable disease associated with asbestos exposure, and the number of affected patients will increase in the coming decades. The clinical outcome assoc...
This paper references
10.1158/1078-0432.CCR-11-1990
CD26 Overexpression Is Associated with Prolonged Survival and Enhanced Chemosensitivity in Malignant Pleural Mesothelioma
K. Aoe (2012)
10.1016/j.ejca.2013.11.032
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.
S. Laurie (2014)
10.1200/JCO.2006.06.8999
Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose
G. Ceresoli (2006)
10.1038/bjc.2011.334
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer
F. Raja (2011)
10.1016/j.lungcan.2013.11.011
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
P. Zucali (2014)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1016/0169-5002(95)90162-0
Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer.
Y. Sekido (1995)
10.1164/rccm.201404-0658OC
Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.
K. Schelch (2014)
10.1016/j.lungcan.2014.03.006
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
M. Zauderer (2014)
10.1200/JCO.2007.13.1144
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.
S. Ramalingam (2008)
10.3816/CLC.2006.N.003
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.
L. Krug (2006)
10.1158/1078-0432.CCR-04-1940
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
10.1002/cncr.23617
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
D. Jackman (2008)
10.2967/jnumed.108.057174
Assessing Tumor Response to Therapy
W. Weber (2009)
10.1097/JTO.0b013e318248242c
Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report
A. Dudek (2012)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/j.coph.2013.03.010
Novel therapeutic targets in non-small cell lung cancer.
M. Alamgeer (2013)
10.1097/JTO.0b013e3181c5e366
Histone Deacetylase Inhibitors in Malignant Pleural Mesothelioma: Preclinical Rationale and Clinical Trials
P. Paik (2010)
10.1002/ijc.10996
Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF‐C autocrine loops
R. Masood (2003)
10.1038/bjc.2013.368
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
G. Ceresoli (2013)
10.1097/JTO.0000000000000211
Observer Variability in Mesothelioma Tumor Thickness Measurements: Defining Minimally Measurable Lesions
S. Armato (2014)
10.1097/JTO.0b013e3181ec18db
A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
S. Dubey (2010)
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
P. Jänne (2002)
10.1016/j.lungcan.2011.11.014
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
T. Jahan (2012)
10.1517/14728214.2014.964682
Emerging drugs targeting PD-1 and PD-L1: reality or hope?
F. Casaluce (2014)
10.1097/JTO.0b013e318229586e
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509
L. Garland (2011)
10.1016/j.lungcan.2014.05.006
Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.
J. Raphael (2014)
10.1155/2013/572609
A Potential Therapeutic Strategy for Malignant Mesothelioma with Gene Medicine
Y. Tada (2013)
10.1007/s11523-014-0311-3
An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group
E. Tahover (2014)
10.1016/j.lungcan.2011.06.007
The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine.
S. Kao (2012)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1056/NEJMoa1200690
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
10.1016/J.LUNGCAN.2006.08.012
EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
J. Edwards (2006)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction.
J. Klominek (1998)
10.1200/JCO.2006.09.7634
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
10.1097/JTO.0b013e31828c2b26
Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
S. Papa (2013)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
10.1158/1078-0432.CCR-11-2121
A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
D. Le (2011)
10.1165/rcmb.2007-0460OC
mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids.
S. Wilson (2008)
10.1016/j.cllc.2013.12.008
Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
A. Tsao (2014)
10.1038/bjc.2012.545
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
D. Cunningham (2013)
10.1016/j.lungcan.2013.10.013
Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up.
E. Minatel (2014)
10.1016/J.EJCA.2007.08.028
Mesothelin targeted cancer immunotherapy.
R. Hassan (2008)
10.3109/07357909909021421
A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma.
E. O’Reilly (1999)
10.1158/1078-0432.CCR-14-0804
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
R. Hassan (2014)
10.1016/S1470-2045(11)70184-X
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
C. Zhou (2011)
10.1158/1078-0432.CCR-07-1388
Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts
P. Bertino (2008)
10.1097/JTO.0b013e318260dfb9
Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma
D. Fennell (2012)
10.1056/NEJMoa1411087
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
S. Ansell (2015)
10.2217/fon.12.190
Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma.
S. M. Lim (2013)
10.1016/S8756-3452(09)79377-6
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
L. Tanoue (2010)
10.1016/J.LUNGCAN.2004.10.005
Thalidomide in patients with malignant pleural mesothelioma.
P. Baas (2005)
10.1038/cddis.2011.58
The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance
D. Barbone (2011)
10.1016/j.ijrobp.2011.09.027
Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.
K. Rosenzweig (2012)
10.1158/1078-0432.CCR-07-0110
Humanized Anti-CD26 Monoclonal Antibody as a Treatment for Malignant Mesothelioma Tumors
T. Inamoto (2007)
10.1016/j.ejca.2013.05.008
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
M. O'Brien (2013)
10.1200/JCO.2011.29.15_SUPPL.E11072
A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer.
Xuan Bich Trinh (2011)
10.1016/j.lungcan.2012.05.111
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
J. Dowell (2012)
10.1186/1471-2407-14-674
A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice
M. Linch (2013)
10.1016/j.bbrc.2014.04.037
CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells.
E. Komiya (2014)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1016/S1470-2045(13)70125-6
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
W. Buikhuisen (2013)
10.1007/s10549-005-9120-9
Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells
S. Hiscox (2005)
10.1097/JTO.0b013e3182333df5
Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
S. Laurie (2011)
10.1007/s10549-014-3217-y
Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer
Hans-Joachim Lueck (2014)
10.1016/j.ctrv.2009.09.003
Second-line treatment for malignant pleural mesothelioma.
G. Ceresoli (2010)
10.1007/s00280-013-2129-6
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
M. Serova (2013)
Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
R. Lenzi (2002)
10.1007/s00262-014-1609-9
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
L. Calabrò (2014)
10.1016/j.lungcan.2014.08.017
Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials.
A. Mansfield (2014)
10.2174/138945011794751591
Dasatinib: an anti-tumour agent via Src inhibition.
A. Gnoni (2011)
10.1007/s00280-007-0500-1
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma
G. Gordon (2007)
10.3892/IJO.18.5.1093
Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis.
L. Strizzi (2001)
10.1002/path.824
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
L. Strizzi (2001)
10.1038/cddis.2013.258
SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma
N. Crawford (2013)
10.1016/S1556-0864(15)30366-X
The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline
P. Ellis (2006)
10.1016/j.lungcan.2014.08.004
Identification of actionable mutations in malignant pleural mesothelioma.
T. Shukuya (2014)
10.1158/1078-0432.CCR-07-0501
The Therapeutic Efficacy of Anti–Vascular Endothelial Growth Factor Antibody, Bevacizumab, and Pemetrexed against Orthotopically Implanted Human Pleural Mesothelioma Cells in Severe Combined Immunodeficient Mice
Q. Li (2007)
10.1097/JTO.0000000000000383
A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group (NCCTG)-N0321
Y. Zhao (2015)
10.1016/J.LUNGCAN.2005.04.010
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
A. Mathy (2005)
10.1097/JTO.0b013e318191520c
Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
S. Ramalingam (2009)
10.1016/S0140-6736(12)61767-X
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
J. Bissler (2013)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar